ⓘ Ravulizumab

                                     

ⓘ Ravulizumab

Ravulizumab is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

This drug developed by Alexion pharmaceuticals, Inc. in

It was approved by the U.S. food and drug administration in December 2018. In April 2019 European CHMP of the EMA recommended granting a conditional marketing authorisation for ravulizumab.

                                     
  • Emapalumab L04AA40 Cladribine L04AA41 Imlifidase L04AA42 Siponimod L04AA43 Ravulizumab L04AA44 Upadacitinib L04AB01 Etanercept L04AB02 Infliximab L04AB03 Afelimomab
  • prophylaxis and treatment Ravagalimab mab humanized CD40 Crohn s disease Ravulizumab Ultomiris mab humanized C5 Y paroxysmal nocturnal hemaglobinuria, atypical